Ipamorelin, GHRP-2 and GHRP-6 are often compared by their ability to stimulate growth hormone. That is only one dimension of their pharmacology. A larger hormone response does not by itself establish a better treatment or a safer research candidate.

The human literature illustrates different questions. An ipamorelin trial examined postoperative bowel recovery, a GHRP-2 experiment investigated food intake in healthy men, and a GHRP-6 study characterized pharmacokinetics in a small group of volunteers. These are not interchangeable tests of long-term health benefit. Randomized ipamorelin postoperative ileus trial GHRP 2 food intake experiment in healthy men GHRP 6 pharmacokinetic study in nine healthy men

Define what the comparison is meant to show

A mechanistic comparison might examine receptor activity or hormone release. A clinical comparison would need an outcome such as function or disease-related benefit, plus adequate safety assessment. Confusing the two can turn a laboratory observation into an unsupported wellness promise.

Population and setting matter as well. Findings in surgical patients cannot simply be applied to healthy adults seeking changes in body composition. A brief pharmacokinetic study cannot establish chronic safety, and an appetite effect is not equivalent to a beneficial nutritional outcome.

Selectivity claims need their own evidence

Terms such as selective or clean should be tied to the hormones, receptors and conditions actually measured. Failure to observe an effect in a small study does not prove the effect can never occur. A comparison should preserve uncertainty and avoid making a universal claim from a narrow experiment.

AXON's conclusion is that the cited studies support distinct research observations, not a ranking for self-directed use. Current jurisdiction-specific status, product identity and a broader evidence review are necessary for any clinical discussion. This article offers no dosing, combination or administration instructions.